- Home
- NFBK vs KMDA Comparison
NFBK vs KMDA Comparison
Compare NFBK & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- KMDA
- Stock Information
- Founded
- NFBK 1887
- KMDA 1990
- Country
- NFBK United States
- KMDA Israel
- Employees
- NFBK N/A
- KMDA N/A
- Industry
- NFBK Major Banks
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- KMDA Health Care
- Exchange
- NFBK Nasdaq
- KMDA Nasdaq
- Market Cap
- NFBK 496.7M
- KMDA 410.6M
- IPO Year
- NFBK 2007
- KMDA N/A
- Fundamental
- Price
- NFBK $11.45
- KMDA $6.90
- Analyst Decision
- NFBK Buy
- KMDA Strong Buy
- Analyst Count
- NFBK 2
- KMDA 2
- Target Price
- NFBK $13.00
- KMDA $13.00
- AVG Volume (30 Days)
- NFBK 153.5K
- KMDA 50.0K
- Earning Date
- NFBK 10-22-2025
- KMDA 11-12-2025
- Dividend Yield
- NFBK 4.60%
- KMDA 2.90%
- EPS Growth
- NFBK 28.89
- KMDA 27.97
- EPS
- NFBK 0.86
- KMDA 0.32
- Revenue
- NFBK $133,079,000.00
- KMDA $169,517,000.00
- Revenue This Year
- NFBK $8.04
- KMDA $14.49
- Revenue Next Year
- NFBK $23.35
- KMDA $10.12
- P/E Ratio
- NFBK $13.12
- KMDA $20.92
- Revenue Growth
- NFBK 4.86
- KMDA 9.67
- 52 Week Low
- NFBK $9.40
- KMDA $5.17
- 52 Week High
- NFBK $14.39
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- NFBK 47.04
- KMDA 42.54
- Support Level
- NFBK $11.49
- KMDA $6.80
- Resistance Level
- NFBK $11.99
- KMDA $7.15
- Average True Range (ATR)
- NFBK 0.27
- KMDA 0.20
- MACD
- NFBK -0.06
- KMDA -0.00
- Stochastic Oscillator
- NFBK 17.86
- KMDA 15.87
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.